cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cerus Corp
7 own
16 watching
Current Price
$0
$-0.03
(-1.17%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
458.4M
52-Week High
52-Week High
5.95
52-Week Low
52-Week Low
1.76
Average Volume
Average Volume
0.57M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization458.4M
icon52-Week High5.95
icon52-Week Low1.76
iconAverage Volume0.57M
iconDividend Yield--
iconP/E Ratio--
What does the Cerus Corp do?
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was founded in 1991 and is headquartered in Concord, California.
Read More
How much money does Cerus Corp make?
News & Events about Cerus Corp.
Zolmax
2 months ago
StockNews.com upgraded shares of Cerus (NASDAQ:CERS Get Rating) from a sell rating to a hold rating in a research note published on Wednesday morning. A number of other research firms have also recently issued reports on CERS. BTIG Research cut Cerus from a buy rating to a neutral rating in a report...
Ticker Report
2 months ago
StockNews.com upgraded shares of Cerus (NASDAQ:CERS Get Rating) from a sell rating to a hold rating in a report published on Wednesday. Several other brokerages also recently issued reports on CERS. Stephens downgraded shares of Cerus from an overweight rating to an equal weight rating and ...
Business Wire
3 months ago
Cerus Corporation (Nasdaq: CERS) announced today that the Company will participate in two upcoming investor conferences. William Obi Greenman, Cerus president and chief executive officer, is scheduled to be in attendance at BTIGs MedTech, Digital Health, Life Science & Diagnostic Tools...
Zolmax
4 months ago
BTIG Research cut shares of Cerus (NASDAQ:CERS Get Rating) from a buy rating to a neutral rating in a research note published on Friday morning, MarketBeat Ratings reports. CERS has been the subject of several other research reports. Stephens lowered Cerus from an overweight rating to an equal ...
Business Wire
5 months ago
Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2022 and provided product revenue guidance for full-year 2023. Cerus unaudited preliminary product revenue for the fourth quarter of 2022 totaled $44.0 million, representing an increase...
Frequently Asked Questions
Frequently Asked Questions
What is Cerus Corp share price today?
plus_minus_icon
Can Indians buy Cerus Corp shares?
plus_minus_icon
How can I buy Cerus Corp shares from India?
plus_minus_icon
Can Fractional shares of Cerus Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Cerus Corp stocks?
plus_minus_icon
What is today’s traded volume of Cerus Corp?
plus_minus_icon
What is today’s market capitalisation of Cerus Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Cerus Corp?
plus_minus_icon
What percentage is Cerus Corp down from its 52-Week High?
plus_minus_icon
What percentage is Cerus Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.03
(-1.17%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$1.01
$-0.03 (-2.88 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.56
$-0.06 (-2.48 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$8.95
$0.81 (9.95 %)
Novavax, Inc.
Novavax, Inc.
$7.58
$-0.09 (-1.17 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$1.01
$-0.03 (-2.88 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.56
$-0.06 (-2.48 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$8.95
$0.81 (9.95 %)
Novavax, Inc.
Novavax, Inc.
$7.58
$-0.09 (-1.17 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00